Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America

TLDR

Updated 2007 guidelines replace the 2000 version, reflecting new antifungal agents, expanded clinical evidence, and emerging concerns from immunosuppressive therapies. An expert panel of the Infectious Diseases Society of America produced evidence‑based guidelines incorporating 1999‑2006 literature, designed for clinicians treating or at risk for histoplasmosis, and adding pediatric recommendations.

Abstract

Evidence-based guidelines for the management of patients with histoplasmosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 30:688-95). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis. New information, based on publications from the period 1999-2006, are incorporated into this guideline document. In addition, the panel added recommendations for management of histoplasmosis in children for those aspects that differ from aspects in adults.